Document:

Exhibit 4(j)

                         RESEARCH AND LICENSE AGREEMENT

                                    AMENDMENT

       THIS AGREEMENT is between RHODE ISLAND HOSPITAL CORPORATION, a
not-for-profit Rhode Island corporation having offices at 593 Eddy Street,
Providence, RI 02903 ("RIH") and NYMOX CORPORATION, a corporation having its
principal place of business at 230 West Passaic Street, Maywood, NJ 07607
("NYMOX") to amend their existing Research and License Agreement (effective date
March 1, 1999) (the "AGREEMENT") to include the following changes:

1. The definitions of TECHNOLOGY, LICENSE FIELD, and PRODUCT in the AGREEMENT
are extended to "research, diagnostic, or therapeutic" by inserting the word
"research," before the words "diagnostic or therapeutic" in line 3 of the second
WHEREAS in the preamble ("TECHNOLOGY") and in line 2 of paragraph 1.9 ("LICENSE
FIELD") and by replacing the word "diagnostic" in line 1 of paragraph 1.14
("PRODUCT") with the phrase "research, diagnostic, or therapeutic."

2. The definition of FIELD OF RESEARCH in paragraph 1.4 is extended by replacing
the existing paragraph with the following definition:

       1.4.   The term "FIELD OF RESEARCH" shall mean research pertaining to the
              use of:

              (a) any form of neural thread protein, antibodies or antibody
              variants to neural thread proteins, specific binding or blocking
              molecules to neural thread proteins, and any cDNAs or genes or
              genomic fragments coding for neural thread proteins;

              (b) gene transfer technology and transgenic or genetically
              transfected or variants thereof animals or cell lines or
              subcellular fractions; and

              (c) any form of AF-20 or the AF-20 antigen, antibodies or antibody
              variants to any form of AF-20, specific binding or blocking
              molecules to any form of AF-20 or the AF-20 antigen, and any cDNAs
              or genes or genomic fragments coding for any form of AF-20 or the
              AF-20 antigen

              for any purpose including (but not limited to) diagnostic,
              therapeutic or research purposes.

3. The words "mice or cell lines" in line 2 of paragraph 1.6 (RIH MATERIAL) are
replaced by the words "animals or cell lines or subcellular fragments."
<PAGE>

4. The word "and" in line 3 and line 7 of paragraph 1.7 (INVENTION) is replaced
by the word "or".

5. The definition of PATENT RIGHT in paragraph 1.12 is amended by adding a new
subparagraph (a) and renumbering the other subparagraphs accordingly. The added
subparagraph is "(a) the United States Patent Application Serial No.
________________ filed on _____________, 2001 entitled "Inhibition of
Neurodegeneration"."

6. The definition of SPONSORED RESEARCH in paragraph 1.18 is amended by
inserting after the words "EFFECTIVE DATE" the words "and includes scientific
research performed by an INVESTIGATOR".

7. In accordance with paragraph 2.4(c) of the Agreement, the Research Plan
appended hereto as Appendix A (the "NEW RESEARCH PROPOSAL") is added to the
AGREEMENT as a RESEARCH PROPOSAL and replaces the existing RESEARCH PROPOSAL.
For the purposes of the AGREEMENT, the EFFECTIVE DATE for the part of the NEW
RESEARCH PROPOSAL entitled "Molecular targeting of human tumors" shall be
November 1, 2001. Upon the execution of this Amendment, any obligation on the
part of NYMOX to fund the existing RESEARCH PROPOSAL shall cease and be replaced
by the obligation to fund the NEW RESEARCH PROPOSAL provided for in this
Amendment.

8. NYMOX agrees to support the NEW RESEARCH PROPOSAL with the annual grants in
accordance with the budget contained in Appendix E as follows:

       a)     For "Studies on neurodegeneration"

              Annual grants of one hundred and seventy-two thousand dollars
              ($172,000) for each of the three (3) years beginning March 1,
              2002, payable on a quarterly basis in the amount of forty-three
              thousand dollars ($43,000) for each of the twelve (12) consecutive
              calendar quarters beginning on March 1, 2002.

       b)     For "Molecular targeting of human tumors"

              Annual grants of seventy-seven thousand dollars ($77,000) for each
              of the three (3) years beginning November 1, 2001, payable on a
              quarterly basis in the amount of nineteen thousand two hundred and
              fifty dollars ($19,250) for each of the twelve (12) consecutive
              calendar quarters beginning on November 1, 2001.

9. NYMOX hereby requests a license to the United States Patent Application
Serial No. 09/872,968 filed on June 1, 2001 entitled "Inhibition of
Neurodegeneration" (the "Patent Application") pursuant to paragraph 6.1 of the
AGREEMENT and RIH hereby grants NYMOX a license pursuant to the AGREEMENT to the
Patent Application and any PATENT RIGHTS relating to the Patent Application, its
claims and the INVENTIONS disclosed in it.

                                      -2-
<PAGE>

IN WITNESS WHEREOF RIH and NYMOX have caused this instrument to be executed.

NYMOX CORPORATION                        RHODES ISLAND HOSPITAL CORPORATION

By:   "Paul Averback"                    By:    "Boyd P. King"
   ------------------------------           ------------------------------------
   Title:   Paul Averback, MD               Title:   Boyd P. King, MD
   CEO and President                        Senior Vice President, Medical
                                            Affairs

Date:    11/22/01                        Date:    11/19/01
     ----------------------------             ----------------------------------

By:      "Roy Wolvin"
   ------------------------------
Title:   Roy Wolvin CFO

Date:    11/23/01
     ----------------------------

I have read the foregoing Amendment and agree to comply with the obligations of
the Principal Investigator created in consequence of this Amendment to the
AGREEMENT.

By:     "JR Wands"                       By:     "SM de la Monte"
   ------------------------------           ------------------------------------
   Jack Wands, MD                           Suzanne de la Monte, MD

Date:    "10/30/01"                      Date:    "30 Oct 2001"
     ----------------------------             ----------------------------------

                                      -3-Exhibit 10.11

                        THIRD AMENDMENT TO LOAN AGREEMENT
                               AND REVOLVING NOTE

         This Third Amendment to Loan Agreement and Revolving Note is made and
entered into this 20th day of June, 2002, by and between U.S. Bank National
Association, a national banking association, with an address of 141 North Main
Avenue, Post Office Box 5308, Sioux Falls, South Dakota 57117-5308 ("Lender")
and Daktronics, Inc., a South Dakota corporation, with an address of 331 32nd
Avenue, Brookings, South Dakota 57006 ("Borrower").

                                    RECITALS:

         A. Lender and Borrower entered into a Loan Agreement dated October 14,
1998, which Loan Agreement was amended by an Amendment dated November 30, 1999
and an Amendment dated December 8, 2000.

         B. In accordance with the Loan Agreement, Lender is the holder of a
Revolving Note dated October 14, 1998 signed on behalf of Borrower. Pursuant to
the Amendment to Loan Agreement dated November 30, 1999, the loan amount is
$20,000,000.00 (the "Revolving Loan").

         C. Lender and Borrower mutually wish to extend the maturity date of the
Revolving Loan from October 1, 2003 to October 1, 2004 and modify some of the
covenants of Borrower.

         NOW, THEREFORE, for good and valuable consideration, the parties agree
as follows:

         1. The Revolving Loan Maturity Date is extended to October 1, 2004.

         2. Section 6.1(e) of the Loan Agreement, requiring quarterly statements
from the Borrower as to no Default or Event of Default, is deleted.

         3. Section 6.10 of the Loan Agreement is amended to read as follows:

                  Merger. The Borrower may merge, consolidate or enter into an
         analogous reorganization without the prior written consent of the
         Lender, provided that the transaction is valued at less than
         $1,000,000.00 and the Borrower is in compliance with all covenants and
         conditions of this Loan Agreement.

                                       50
<PAGE>

         4. Section 6.11 of the Loan Agreement is amended to read as follows:

                  Acquisitions. The Borrower will not acquire during any fiscal
         year another business, firm or company in excess of $1,000,000.00,
         without prior written approval from the Lender.

         5. Schedule VI is amended to provide with respect to the Tangible Net
Worth covenant:

                  Tangible Net Worth. The Borrower will not permit its Tangible
         Net Worth (the excess of its assets, excluding intangible assets, over
         its liabilities) at any time to be less than $40,000,000.00.

         6. Schedule VI is further amended to provide with respect to the
definition of "Adjusted Fixed Charge Coverage Ratio":

                  Minimum Adjusted fixed Charge Coverage Ratio. The Borrower
         will not permit the Minimum Adjusted Fixed Charge Ratio, as of the last
         day of any fiscal year for the four consecutive fiscal quarters ending
         on that date to be less than 2 to 1.

                  For purposes hereof, the following definitions have the
following meanings:

                  "EBITDA": For any period of determination, the net income of
the Borrower before deductions for income taxes, interest expense, depreciation
and amortization, all as determined in accordance with GAAP.

         "Adjusted Fixed Charge Coverage Ratio": For any period of determination
         with respect to the Borrower, the ratio of

                  (a) EBITDA minus the sum of (i) any dividends or other
                  distributions, (ii) expenditures in the sum of $1,500,000.00
                  for fixed and capital assets not financed and (iii) tax
                  expenses,

                  to

                  (b) all required principal and interest payments with respect
                  to Indebtedness (including but not limited to all payments
                  with respect to capitalized lease obligations of the
                  Borrower), in each case determined for said period in
                  accordance with GAAP.

         9. Section 6.1(a) is amended to read as follows:

                                       51
<PAGE>

         6.1(a) As soon as available in any event within ninety (90) days after
         the end of each fiscal year of the Borrower, financial statements of
         income cash flow and changes in stockholders' equity, a balance sheet
         as at the end of such year, and notes thereto, setting forth each case
         in comparative form corresponding figures from the previous annual
         audit, certified without qualification by an independent Certified
         Public Accountant of recognized regional standing selected by the
         Borrower. Provided Borrower is in compliance with all filing
         requirements of the Securities and Exchange Commission and timely files
         all of the above information with the Securities and Exchange
         Commission and within the timeframes required above, Borrower shall not
         be obligated to provide such financial information to the Lender.

         8. The following sentence is added to the end of Section 6.1(b):

                  Provided Borrower is in compliance with all filing
         requirements of the Securities and Exchange Commission and timely files
         all of the above information with the Securities and Exchange
         Commission and within the timeframes required above, Borrower shall not
         be obligated to provide such information directly to the Lender.

         9. Sections 6.1(c) and 6.1(d) are deleted in their entirety.

         10. All other terms and conditions of the Loan Agreement and Revolving
Note shall remain in full force and effect except as modified herein.

DAKTRONICS, INC.                              U.S. BANK NATIONAL ASSOCIATION

By  /s/ William R. Retterath                  By /s/ Carl Wynja
    ---------------------------                  ---------------------------
William R. Retterath                          Carl Wynja
Chief Financial Officer                       Vice President

                                       52

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00040-of-00352.parquet"}]]